Carlsmed, Inc. (NASDAQ:CARL – Get Free Report) has received a consensus recommendation of “Hold” from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $19.3333.
A number of brokerages have commented on CARL. Wall Street Zen downgraded shares of Carlsmed from a “hold” rating to a “sell” rating in a research note on Saturday. BTIG Research reaffirmed a “buy” rating and set a $23.00 target price on shares of Carlsmed in a research note on Wednesday, May 6th. Truist Financial reduced their target price on shares of Carlsmed from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, April 15th. The Goldman Sachs Group reduced their target price on shares of Carlsmed from $19.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Finally, Zacks Research raised shares of Carlsmed from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 26th.
Check Out Our Latest Stock Report on Carlsmed
Carlsmed Stock Performance
Carlsmed (NASDAQ:CARL – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.11. The firm had revenue of $16.12 million for the quarter. Carlsmed had a negative net margin of 57.76% and a negative return on equity of 60.74%. Equities analysts anticipate that Carlsmed will post -1.35 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Carlsmed
Institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new position in Carlsmed during the third quarter worth about $33,000. JPMorgan Chase & Co. purchased a new position in Carlsmed during the third quarter worth about $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Carlsmed during the third quarter worth about $42,000. Rhumbline Advisers purchased a new position in Carlsmed during the third quarter worth about $79,000. Finally, Wells Fargo & Company MN raised its stake in Carlsmed by 61.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,834 shares of the company’s stock worth $97,000 after purchasing an additional 2,989 shares during the period.
Carlsmed Company Profile
We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).
Read More
- Five stocks we like better than Carlsmed
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for Carlsmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carlsmed and related companies with MarketBeat.com's FREE daily email newsletter.
